000283157 001__ 283157
000283157 005__ 20260109160351.0
000283157 0247_ $$2doi$$a10.1002/alz.71049
000283157 0247_ $$2pmid$$apmid:41505233
000283157 0247_ $$2ISSN$$a1552-5260
000283157 0247_ $$2ISSN$$a1552-5279
000283157 037__ $$aDZNE-2026-00053
000283157 041__ $$aEnglish
000283157 082__ $$a610
000283157 1001_ $$aSchultz, Stephanie A$$b0
000283157 245__ $$aPlasma levels of an N-terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's disease.
000283157 260__ $$aHoboken, NJ$$bWiley$$c2026
000283157 3367_ $$2DRIVER$$aarticle
000283157 3367_ $$2DataCite$$aOutput Types/Journal article
000283157 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767970835_5997
000283157 3367_ $$2BibTeX$$aARTICLE
000283157 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000283157 3367_ $$00$$2EndNote$$aJournal Article
000283157 520__ $$aTau species lacking truncation of the N-terminal region, including plasma N-terminal tau fragment 1 (NT1), have been previously associated with cognitive decline, neurodegeneration, and tau pathology in late-onset sporadic Alzheimer's disease (AD).Here, we examined cross-sectional and longitudinal plasma NT1 as a possible predictor of cognitive, clinical, and core AD biomarker trajectories in autosomal dominant AD (ADAD).NT1 levels in ADAD mutation carriers (MC; n = 132) increased across the disease continuum, compared to non-carriers (NC; n = 75), becoming elevated about a decade prior to estimated symptom onset. Cross-sectional and longitudinal NT1 levels in MC were associated with clinical, cognitive, and biomarker changes. NT1 increases continued in symptomatic phases of disease, a distinct trajectory from that seen with CSF p-tau217 and other phospho-tau species.Together, our results suggest that plasma NT1-alone or combined with other tau measures-may be useful in studying AD-related clinical, cognitive, and biomarker outcomes.Leveraging a deeply phenotyped cohort of individuals carrying a pathogenic variant for autosomal dominant Alzheimer's disease (ADAD) and their non-carrier family members, our results suggest that plasma N-terminal tau fragment 1 (NT1) levels mirrored changes in clinical, cognitive, and neurodegenerative measures in ADAD, particularly in late asymptomatic and early symptomatic phases of disease. NT1 levels correlated with cerebrospinal fluid (CSF) measures of tau pathology but less so with CSF or imaging measures of β-amyloid pathology. Together with previous supportive findings in preclinical and symptomatic sporadic AD, these results suggest that plasma NT1-alone or combined with other tau measures-may be useful in studying AD-related tau pathology and neurodegeneration across a wide spectrum of disease.
000283157 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000283157 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x1
000283157 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000283157 650_7 $$2Other$$aADAD
000283157 650_7 $$2Other$$abiomarker
000283157 650_7 $$2Other$$aneurodegeneration
000283157 650_7 $$2Other$$atauopathy
000283157 650_7 $$2NLM Chemicals$$atau Proteins
000283157 650_7 $$2NLM Chemicals$$aBiomarkers
000283157 650_7 $$2NLM Chemicals$$aPeptide Fragments
000283157 650_7 $$2NLM Chemicals$$aMAPT protein, human
000283157 650_2 $$2MeSH$$aHumans
000283157 650_2 $$2MeSH$$atau Proteins: blood
000283157 650_2 $$2MeSH$$aAlzheimer Disease: blood
000283157 650_2 $$2MeSH$$aAlzheimer Disease: genetics
000283157 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000283157 650_2 $$2MeSH$$aBiomarkers: blood
000283157 650_2 $$2MeSH$$aMale
000283157 650_2 $$2MeSH$$aFemale
000283157 650_2 $$2MeSH$$aCross-Sectional Studies
000283157 650_2 $$2MeSH$$aMiddle Aged
000283157 650_2 $$2MeSH$$aLongitudinal Studies
000283157 650_2 $$2MeSH$$aPeptide Fragments: blood
000283157 650_2 $$2MeSH$$aAged
000283157 650_2 $$2MeSH$$aNeurodegenerative Diseases: blood
000283157 693__ $$0EXP:(DE-2719)DIAN-20090101$$5EXP:(DE-2719)DIAN-20090101$$eLongitudinal Study on Dominantly Inherited Alzheimer's Disease$$x0
000283157 7001_ $$aRao, Yiwen$$b1
000283157 7001_ $$aLiu, Lei$$b2
000283157 7001_ $$aOstaszewski, Beth$$b3
000283157 7001_ $$aAnderson, Amirah K$$b4
000283157 7001_ $$aYau, Wai-Ying Wendy$$b5
000283157 7001_ $$aShirzadi, Zahra$$b6
000283157 7001_ $$aGordon, Brian A$$b7
000283157 7001_ $$aHassenstab, Jason$$b8
000283157 7001_ $$aMorris, John C$$b9
000283157 7001_ $$aPerrin, Richard J$$b10
000283157 7001_ $$aAllegri, Ricardo F$$b11
000283157 7001_ $$aBarthélemy, Nicolas R$$b12
000283157 7001_ $$aFox, Nick$$b13
000283157 7001_ $$aDay, Gregory S$$b14
000283157 7001_ $$0P:(DE-2719)2000010$$aJucker, Mathias$$b15$$udzne
000283157 7001_ $$aLevey, Allan I$$b16
000283157 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b17$$udzne
000283157 7001_ $$aMori, Hiroshi$$b18
000283157 7001_ $$aSalloway, Stephen$$b19
000283157 7001_ $$aSchofield, Peter$$b20
000283157 7001_ $$aMcDade, Eric$$b21
000283157 7001_ $$aSperling, Reisa A$$b22
000283157 7001_ $$aBateman, Randall J$$b23
000283157 7001_ $$aSelkoe, Dennis J$$b24
000283157 7001_ $$aChhatwal, Jasmeer P$$b25
000283157 7001_ $$aNetwork, and the Dominantly Inherited Alzheimer's$$b26$$eCollaboration Author
000283157 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.71049$$gVol. 22, no. 1, p. e71049$$n1$$pe71049$$tAlzheimer's and dementia$$v22$$x1552-5260$$y2026
000283157 8564_ $$uhttps://pub.dzne.de/record/283157/files/DZNE-2026-00053.pdf$$yRestricted
000283157 8564_ $$uhttps://pub.dzne.de/record/283157/files/DZNE-2026-00053.pdf?subformat=pdfa$$xpdfa$$yRestricted
000283157 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000010$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000283157 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b17$$kDZNE
000283157 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000283157 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x1
000283157 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283157 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283157 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283157 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283157 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283157 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283157 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283157 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283157 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283157 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283157 9201_ $$0I:(DE-2719)1210001$$kAG Jucker$$lCell Biology of Neurological Diseases$$x0
000283157 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x1
000283157 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x2
000283157 980__ $$ajournal
000283157 980__ $$aEDITORS
000283157 980__ $$aVDBINPRINT
000283157 980__ $$aI:(DE-2719)1210001
000283157 980__ $$aI:(DE-2719)1111015
000283157 980__ $$aI:(DE-2719)1111016
000283157 980__ $$aUNRESTRICTED